Mitapivat|PKM2 activator|cas 1260075-17-9

Cas No.:	1260075-17-9
Chemical Name:	N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Synonyms:	N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
SMILES:	O=S(=O)(NC1C=CC(C(=O)N2CCN(CC3CC3)CC2)=CC=1)C1C=CC=C2C=1N=CC=C2
Formula:	C₂₄H₂₆N₄O₃S
M.Wt:	450.553244113922
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Mitapivat is a potent human R-type pyruvate kinase (PKR) inhibitor; also shows potency for mutant PKR including R510Q PKR, R532W PKR, T384W PKR etc.
References:	[1]. PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY. Patent WO/2012/151451A1

Cat. No.	Product name	Field of application
DC47090	Etavopivat	Etavopivat is a potent, selective, orally bioavailable red blood cell (RBC) pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects.
DC10568	Mitapivat	Mitapivat is an activator of pyruvate kinase isoenzyme M2 (PKM2),
DC8647	DASA-58	DASA-58 is a highly specific small molecule PKM2 activator. DASA-58 inhibits LPS-induced Hif-1a and IL-1b, as well as the expression of a range of other Hif-1a-dependent genes.